REGENXBIO, Inc. (NASDAQ:RGNX) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Patrick Christmas – Chief Legal Officer Ken Mills – President and Chief Executive Officer Steve Pakola – Chief Medical Officer Vit Vasista – Chief Financial Officer Conference Call Participants Gena Wang – Barclays Alec Stranahan – Bank of America Mani Foroohar – SVB Sam Lee – Chardan Connor McGuinness Meehan – Morgan Stanley Luca Issi – RBC Capital Operator Good afternoon and welcome to the REGENXB ...

Commission File Number 001-37553 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ REGENXBIO Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1851754 (State ...

Corporate Presentation Leader in AAV Gene Therapy June 16, 2020 Forward-looking statements This presentation includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," ...

REGENXBIO, Inc. (NASDAQ:RGNX) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET Company Participants Patrick Christmas - Senior Vice President and General Counsel Kenneth Mills - President and Chief Executive Officer Stephen Pakola - Chief Medical Officer Vittal Vasista - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Gbola Amusa - Chardan Capital Markets Mani Foroohar - SVB Leerink Costas Liappas - Morgan Stanley Operator Good afternoon, and welcome to the REGENXBIO First Q ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 9600 Blackwell Road, Suite 210 Rockville, MD 20850 (Address of principal executive offices) (Zip Code) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001 ...

REGENXBIO, Inc. (NASDAQ:RGNX) Q4 2019 Earnings Conference Call February 26, 2020 4:30 PM ET Company Participants Patrick Christmas - Senior Vice President and General Counsel Kenneth Mills - President and Chief Executive Officer Stephen Pakola - Chief Medical Officer Vittal Vasista - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Connor Meehan - Morgan Stanley Gbola Amusa - Chardan Capital Markets Mani Foroohar - SVB Leerink Operator Good afternoon, and welcome to the REGENXBIO Fo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37553 REGENXBIO Inc. (Exact name of registrant as specified in its charter) Delaware 47-1851754 (State or other ju ...

REGENXBIO, Inc. (NASDAQ:RGNX) Q3 2019 Earnings Conference Call November 5, 2019 4:30 PM ET Company Participants Patrick Christmas - Senior Vice President and General Counsel Kenneth Mills - President and Chief Executive Officer Stephen Pakola - Chief Medical Officer Vittal Vasista - Chief Financial Officer Conference Call Participants Gena Wang - Barclays PLC Mani Foroohar - SVB Leerink Kostas Biliouris - Morgan Stanley Operator Good afternoon, and welcome to the REGENXBIO Third Quarter 2019 Earnings Confer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-37553 REGENXBIO Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1851754 (S ...

Corporate Presentation Leader in AAV Gene Therapy September 6, 2019 Forward-looking statements This presentation includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipat ...